NEW YORK (GenomeWeb News) – Cell Biosciences on Wednesday said that it had completed the acquisition of Alpha Innotech.

Santa Clara, Calif.-based Cell Biosciences will pay Alpha Innotech's shareholders $1.50 per share, giving the deal a total consideration of $17.9 million.

The firms announced the deal in early September.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.